BOLT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
5.0K
-80.8%
26.0K
-99.0%
2.5M
+15.3%
2.2M
+20.2%
1.8M
Cost of Revenue
0
0
0
0
0
Gross Profit
5.0K
-80.8%
26.0K
-99.0%
2.5M
+15.3%
2.2M
+20.2%
1.8M
Operating Expenses
8.4M
+9.9%
7.6M
-20.4%
9.6M
-2.9%
9.9M
-10.4%
11.0M
R&D
5.1M
+6.6%
4.8M
-3.2%
5.0M
-23.7%
6.5M
-12.8%
7.5M
SG&A
2.4M
-13.4%
2.8M
-10.2%
3.1M
-6.6%
3.3M
-5.1%
3.5M
Operating Income
-8374000
-10.2%
-7601000
-7.3%
-7085000
+8.0%
-7703000
+16.4%
-9210000
EBITDA
-7395000
+0.0%
-7398000
-38.3%
-5350000
+27.8%
-7413000
+16.4%
-8863000
Net Income
-7720000
-6.6%
-7244000
-9.2%
-6631000
+7.2%
-7144000
+16.6%
-8561000
EPS (Basic)
$-4.57
-6.0%
$-4.31
-12.2%
$-3.84
-3.2%
$-3.72
+16.6%
$-4.46
EPS (Diluted)
$-4.57
-6.0%
$-4.31
-12.2%
$-3.84
-3.2%
$-3.72
+16.6%
$-4.46
Shares (Diluted)
1.7M
+0.6%
1.7M
-2.6%
1.7M
-10.1%
1.9M
+0.1%
1.9M
Bolt Biotherapeutics (BOLT) โ€” Financials